News
Despite US policy changes, drug prices stay stubbornly high
US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
News
GSK wins FDA green light for chronic hep B treatment Hibsago
GSK's antisense-based drug for chronic hepatitis B virus (HBV) infection, Hibsago, has been approved in the US, its second major market after Japan.
Market Access
Sponsored
The pre-commercial case for connecting data before acquiring...
For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.
News
Compounded tirzepatide recalled after FDA warning
A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide has been recalled from sale due to sterility concerns.
News
Jemperli label extended to include rectal cancer
GSK's PD-1 inhibitor Jemperli has been cleared by the FDA as the first pre-operative cancer immunotherapy for rectal cancer.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
